The prognosis of patients with co-morbid diabetes and hepatitis B and strategies for improving outcome

Abstract

The relationship between diabetes and hepatitis B remains unclear. We have found that there is no general correlation between the incidence of diabetes and hepatitis B, except in certain populations. Patients with co-existing diabetes and hepatitis B tend to have poorer overall prognoses, primarily evidenced by an increased risk of hepatocellular carcinoma (HCC) and all-cause mortality within this population. The optimal selection of medication for these patients should take long-term prognosis into account. To improve long-term outcomes, we recommend specific anti-diabetic medications for this group. Additionally, it is advisable to administer the hepatitis B vaccine as soon as possible following a diagnosis of diabetes in order to enhance the patient's prognosis. Increased attention from health management authorities, revisions of relevant guidelines, and advancements in educational initiatives may also improve outcomes for this demographic.